Latest Capital Raises News

Cosmo Metals has locked in a diamond drill rig to advance its high-impact program at the Kanowna Gold Project, targeting deep gold mineralisation near the Fitzroy Fault with government co-funding.

Delorean Corporation has launched a $2.2 million Share Purchase Plan at $0.09 per share, matching a recent strategic placement to LMS Energy. The capital raise supports construction of key bioenergy projects in South Australia and New South Wales.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

Celsius Resources is probing an unauthorized directive by an executive to transfer shares in Makilala Mining, leading to the termination of the executive's consulting role amid ongoing ownership conflicts.

Arcadia Minerals (ASX: AM7) has denied possessing any undisclosed information following a sharp rise in its share price and volume. The company retracted parts of a recent market update related to its negotiations with Xinhai Mining Services and confirmed compliance with ASX disclosure rules.

NeuRizer Ltd advanced its urea project with Reliance Industries payments and environmental submissions, despite ongoing ASX trading suspension and overdue financial reports.

Beetaloo Energy has secured full underwriting for its $5 million Share Purchase Plan, with shareholder approval for the share issuance and any shortfall shares to be sought at the upcoming AGM on 29 May 2026.

Stellar Resources has raised $22.1 million through a placement led by Metals X, boosting its cash reserves to $33 million and setting the stage for key feasibility studies at Heemskirk.

Legacy Minerals reveals a robust 19-year Mt Carrington gold-silver project with a pre-tax NPV of A$716 million and low operating costs, advancing towards pre-feasibility studies amid resource conversion plans.

Zimi Limited secures A$1.4 million via a discounted share placement, including director participation, to fund manufacturing and sales expansion.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

Navigator Global Investments (ASX: NGI) is acquiring a US$195 million portfolio of Net Revenue Share interests from Stable Asset Management, broadening its alternative asset manager ecosystem and raising A$145 million via a fully underwritten entitlement offer.